Copyright: ©Author(s) 2026.
World J Gastroenterol. Nov 21, 2026; 32(43): 121944
Published online Nov 21, 2026. doi: 10.3748/wjg.121944
Published online Nov 21, 2026. doi: 10.3748/wjg.121944
| Treatment | Disease | Methods | Model | Therapies | Consequence | Mechanism | Ref. |
| FMT | Colorectal cancer | Mouse models of colorectal cancer were established by orthotopic, subcutaneous colorectal allotransplantation and xenotransplantation | Germ-free, CD34+ humanized mice | Stool samples for FMT were suspended in sterile PBS, given to mice by gavage | Enhance the efficacy of PD-1 therapy in colorectal cancer | Inhibit the expression of PD-1 in cancer cells, alleviate the exhaustion of CD8+ T cells, and promote the function of effector T cells | Wang et al[213] |
| Activate the sympathetic fibers | Colitis | DSS-induced colitis model | SPF mice | An optogenetic probe was inserted intra-rectally to transgenic mice expressing the optogenetic channel, ChR2 in TH expressing cells | Attenuate the clinical symptoms of the DSS-induced colitis and diminished immune cell abundance in the inflamed site | Reduce MAdCAM-1 expression on endothelial cells | Schiller et al[214] |
| ASAH1 inhibitor | Colorectal cancer | CT26 cells allogeneic transplantation-induced colorectal cancer mice model | NOD-SCID mice and BALB/c mice | Intraperitoneal injection | Compared to immunodeficient mice, silencing ASAH1 significantly reduced the final tumor volume and tumor weight | Enhance the infiltration of CD8+ T cells and M1 macrophages | Vijayan et al[215] |
| Oral surfactin | Colitis | DSS-induced colitis model | Kunming male mice | Mice treated with orally administered 80 mg/kg body weight surfactin per day | Oral surfactin ameliorate intestinal dysbiosis, colon and brain inflammation, and behavior disorders | Up-regulate the expression of tight junction proteins and inhibits inflammatory signaling pathways | Chen et al[216] |
| 2’,4’-DHC | Colorectal cancer | CT26 cells allogeneic transplantation-induced colorectal cancer mice model | BALB/c mice | Mice are received 2’,4’-DHC gavage | Significantly inhibit growth of tumor | Inhibit NLRP3 inflammasome through the NF-κB pathway, increasing caspase-3/4/11 activation, enhance the anticancer immune response by regulating the infiltration and function of T cells and macrophages | Zhang et al[217] |
| FCT: A synbiotic combination of Lactobacillus gasseri 505 and Cudrania tricuspidata leaf extract | Colorectal cancer | AOM/DSS-induced colorectal cancer mice model | C57BL/6 mice | FCT is administered orally in the colorectal cancer mice | The FCT administration showed cancer-protective effects | Promote the expression of tight junction protein to repair colon barrier, up-regulate P53 and inhibit the apoptosis of cancer cells induced by Bcl-2 | Oh et al[218] |
| Denervation | Gastric cancer | APC gene knockout | Apcmin (min: Multiple intestinal neoplasia)/+ k/o mice | Subdiaphragmatic vagotomy | Denervation reduce tumor incidence and progression | Inhibit the activation of the ERK1/2 signaling pathway, inflammation response, and cellular proliferation by reducing the activation of M3R and α7nAChR | Liu et al[219] |
| Denervation | Gastric cancer | Overexpression of gastrin produces spontaneous gastric cancer | INS-GAS mouse model | Subdiaphragmatic bilateral truncal vagotomy unilateral vagotomy, or Botox local injection | Denervation of the stomach markedly reduce tumor incidence and progression | Inhibit Wnt signaling and suppress stem cell expansion via M3 receptor | Zhao et al[220] |
| 5-HT inhibitor | Colorectal cancer | Colorectal cancer model is established by injecting patient-derived CRC tumor cells | B-NSG mice | Mice are injected with 5-FU and methiothepin in tumor | Significantly inhibit tumor growth | Blocking 5-HT signaling pathway can inhibit the self-renewal and proliferation of colorectal cancer stem cells | Zhu et al[121] |
- Citation: Xu X, Qu CK, Bao LL, Zhang YX, Wang WJ, Ye YQ. Bridge of imbalance: How does the brain-gut axis act as a catalyst for gastrointestinal tumors in aging. World J Gastroenterol 2026; 32(43): 121944
- URL: https://www.wjgnet.com/1007-9327/full/v32/i43/121944.htm
- DOI: https://dx.doi.org/10.3748/wjg.121944